Oxford University will start human testing with a Covid-19 vaccine they developed from Thursday, the UK government said in a coronavirus press conference.

The Oxford team – led by Professor Sarah Gilbert, is testing ChAdOx1 nCoV-19, a candidate based on a chimpanzee adenovirus modified to include the spike or ‘S’ protein on the surface of SARS-CoV-2, the virus that causes Covid-19.

The government funded the vaccine project with 20 million pounds to Oxford University and another 22 million pounds to a second vaccine project at Imperial College, London, Health Secretary Matt Hancock said on Wednesday, adding the project will help support phase 2 trials and help prepare for a larger phase 3 study.

Hancock said a vaccine is the "best way" to defeat the virus and the bring the number of cases down in the country.

He said the UK government is committed to provide financial support to build manufacturing capacity for vaccines if they prove effective in clinical testing.

The testing came as the death toll from coronavirus in the UK crossed the 18,000 mark. The global toll has already crossed 184,000

The vaccine will be tested on around 500 volunteers and will focus on safety and tolerability, as well as providing an initial assessment of how effective the shot is.

The Imperial candidate has been developed by a team led by Professor Robin Shattock and is an mRNA vaccine against the S protein on SARS-CoV-2 – using a similar approach to a vaccine developed by US biotech Moderna which is already in clinical trials.

“Both of these promising projects are making rapid progress and I've told the scientists leading them we will do everything in our power to support them,” said Hancock.

A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (https://www.pulsus.com/submissions/biomolecules-biochemistry.html) or Author may submit their manuscripts as an e-mail attachment to the Editorial Office at: biomolecules@molecularbiologyjournals.com

How we work:

• After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
• A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
• Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Color Art: In a world of black & white journal articles, high-quality full-color images make your article stand out from the crowd and tell a complete story, increasing readers and citations.

Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.

Media Contact:
Mercy| Managing Editor
Journal of Biomolecules and Biochemistry
Whatsapp No:  +1-504-608-2390